Results 61 to 70 of about 2,693 (166)
Clinical Case Reports, Volume 13, Issue 10, October 2025.ABSTRACT Both pulmonary tuberculosis (PTB) and coronavirus disease‐2019 (COVID‐19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of Achromobacter spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID‐19.
Marius Paulin Ngouanom Kuate +2 more
wiley +1 more source
Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
Infection and Drug Resistance, 2022 Ryota Ito, Masato Kawamura, Takumi Sato, Shigeru Fujimura Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, Sendai, Miyagi, JapanCorrespondence: Ryota Ito, Tohoku Medical and Pharmaceutical University,
Ito R, Kawamura M, Sato T, Fujimura S
doaj
PharmaceuticalsAntimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs +3 more
doaj +1 more source
Investigation on Klebsiella pneumoniae in the field of extracellular vesicles
Interdisciplinary Medicine, Volume 3, Issue 4, July 2025.The role of extracellular vesicles in the pathogenicity and antibiotic resistance, as well as treatment and prevention of Klebsiella pneumoniae. Abstract Klebsiella pneumoniae (KP), recognized for its pronounced antibiotic resistance, is a prevalent agent of nosocomial infections such as hospital‐acquired pneumonia.
Junwei Wu +10 more
wiley +1 more source
Journal of Clinical Laboratory Analysis, Volume 39, Issue 9, May 2025.This review highlights computational approaches for discovering antimicrobials against carbapenem‐resistant Enterobacterales. It outlines methods like pharmacophore modeling, molecular docking, and absorption, distribution, metabolism, and excretion–toxicity (ADMET) analysis, integrated with in vitro assays, to identify and validate potential drugs ...
Muhammad Absar +7 more
wiley +1 more source
Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
Life(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens. New β-lactam/β-lactamase inhibitor combinations are urgently needed.
Sansone, Pasquale +7 more
openaire +4 more sources
PLoS ONE, 2020 Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Islam M Ghazi +5 more
doaj +1 more source
Clinical and Translational Science, Volume 18, Issue 5, May 2025.ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen +3 more
wiley +1 more source
EFSA Journal, Volume 23, Issue 4, April 2025.Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards) +28 more
wiley +1 more source
Microbiology SpectrumWith the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang +13 more
doaj +1 more source